These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 11987434)

  • 21. Portfolio evaluation of health programs: a reply to Sendi et al.
    Bridges JF; Terris DD
    Soc Sci Med; 2004 May; 58(10):1849-51. PubMed ID: 15020002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.
    Rothery C; Strong M; Koffijberg HE; Basu A; Ghabri S; Knies S; Murray JF; Sanders Schmidler GD; Steuten L; Fenwick E
    Value Health; 2020 Mar; 23(3):277-286. PubMed ID: 32197720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An introduction to the methods of cost-effectiveness analysis.
    Drug Ther Bull; 2012 Jul; 50(7):81-4. PubMed ID: 22789768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Methods for analyzing uncertainty].
    Ferriols R; Alós M
    Farm Hosp; 2011 May; 35 Suppl 2():3-9. PubMed ID: 22445503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Portfolio theory and the alternative decision rule of cost-effectiveness analysis: theoretical and practical considerations.
    Sendi P; Al MJ; Gafni A; Birch S
    Soc Sci Med; 2004 May; 58(10):1853-5. PubMed ID: 15020003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integration of probabilistic exposure assessment and probabilistic hazard characterization.
    van der Voet H; Slob W
    Risk Anal; 2007 Apr; 27(2):351-71. PubMed ID: 17511703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of hearing aids in the hearing-impaired elderly: a probabilistic approach.
    Chao TK; Chen TH
    Otol Neurotol; 2008 Sep; 29(6):776-83. PubMed ID: 18725859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addressing risk preferences in cost-effectiveness analyses.
    Zivin JG; Bridges JF
    Appl Health Econ Health Policy; 2002; 1(3):135-9. PubMed ID: 14619264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EUD-based radiotherapy treatment plan evaluation: incorporating physical and Monte Carlo statistical dose uncertainties.
    Cranmer-Sargison G; Zavgorodni S
    Phys Med Biol; 2005 Sep; 50(17):4097-109. PubMed ID: 16177533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Handling uncertainty when performing economic evaluation of healthcare interventions.
    Briggs AH; Gray AM
    Health Technol Assess; 1999; 3(2):1-134. PubMed ID: 10448202
    [No Abstract]   [Full Text] [Related]  

  • 31. Evidence-based priority-setting: what do the decision-makers think?
    Mitton C; Patten S
    J Health Serv Res Policy; 2004 Jul; 9(3):146-52. PubMed ID: 15272972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decision-analytical modelling in health-care economic evaluations.
    Sun X; Faunce T
    Eur J Health Econ; 2008 Nov; 9(4):313-23. PubMed ID: 17943332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modelling in the economic evaluation of health care: selecting the appropriate approach.
    Barton P; Bryan S; Robinson S
    J Health Serv Res Policy; 2004 Apr; 9(2):110-8. PubMed ID: 15099459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simulations in health risk assessment.
    Biesiada M
    Int J Occup Med Environ Health; 2001; 14(4):397-402. PubMed ID: 11885924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uncertainty and patient heterogeneity in medical decision models.
    Groot Koerkamp B; Weinstein MC; Stijnen T; Heijenbrok-Kal MH; Hunink MG
    Med Decis Making; 2010; 30(2):194-205. PubMed ID: 20190188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of stochastic multiattribute analysis to assessment of single walled carbon nanotube synthesis processes.
    Canis L; Linkov I; Seager TP
    Environ Sci Technol; 2010 Nov; 44(22):8704-11. PubMed ID: 20964398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness acceptability curves--caveats quantified.
    Jakubczyk M; Kamiński B
    Health Econ; 2010 Aug; 19(8):955-63. PubMed ID: 19688780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Who's better not best: appropriate probabilistic uncertainty analysis.
    Coyle D
    Int J Technol Assess Health Care; 2003; 19(3):540-5. PubMed ID: 12962341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Handling input correlations in pharmacoeconomic models.
    Naveršnik K; Rojnik K
    Value Health; 2012 May; 15(3):540-9. PubMed ID: 22583465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Priority setting in health care and higher order degree change in risk.
    Courbage C; Rey B
    J Health Econ; 2012 May; 31(3):484-9. PubMed ID: 22531647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.